The anti-coagulants overly ramp up the bodies own system to break down clots which increases the risk of an induced hemophilia. Leronlimab by reducing inflammation shuts down overactive platelet activation factor. By returning the body's platelet production to normal it reduces coagulopathies and thrombosis without inducing bleeding.